問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

蘇文彬

Recruiting

List

143Cases

2023-05-01 - 2025-12-31

Phase I

An Open Label, Phase 1, Treatment Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of IDE397 (MAT2A Inhibitor) In Adult Participants With Advanced Solid Tumors

  • Condition/Disease

    Solid Tumor

  • Test Drug

    IDE397

Participate Sites
2Sites

Recruiting2Sites

2017-01-01 - 2021-12-31

Phase III

A Phase III, Open Label, Randomized Study to Assess the Efficacy and Safety of Olaparib (Lynparza) Versus Enzalutamide or Abiraterone Acetate in Men with Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment with a New Hormonal Agent and Have Homologous Recombination Repair Gene Mutations

  • Condition/Disease

    Metastatic Castration-Resistant Prostate Cancer

  • Test Drug

    Olaparib

Participate Sites
9Sites

Recruiting5Sites

Terminated4Sites

2018-12-01 - 2024-06-21

Phase I

A Phase IB, Open-Label, Multi-Center Study to Determine the Efficacy and Safety of Durvalumab in Combination With Novel Oncology Therapies, With or Without Chemotherapy, for First-Line Stage IV Non Small Cell Lung Cancer (NSCLC) (MAGELLAN)

  • Condition/Disease

    NSCLC

  • Test Drug

    Durvalumab

Participate Sites
9Sites

Recruiting8Sites

李岡遠
Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Thoracic Medicine

楊政達
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2019-02-01 - 2020-12-31

Phase I

A Phase 1, open-label, dose escalation study to evaluate the safety, tolerability, pharmacokinetic and efficacy of NBM-BMX in subjects with advanced solid tumors

  • Condition/Disease

    Malignant Neoplasm

  • Test Drug

    NBM-BMX

Participate Sites
2Sites

Recruiting2Sites

葉裕民
National Taiwan University Hospital

Division of Hematology & Oncology

顏厥全
Taipei Veterans General Hospital

Division of Hematology & Oncology

2020-08-01 - 2025-07-01

Phase I

A Phase 1, Multi-center, Open Label First-in-Human Study With ABBV-CLS-579 Alone and in Combination With Anti-PD-1 in Subjects With Locally Advanced or Metastatic Tumors

  • Condition/Disease

    Locally Advanced or Metastatic Tumors

  • Test Drug

    ABBV-CLS-579

Participate Sites
4Sites

Not yet recruiting1Sites

Recruiting3Sites

2023-07-07 - 2026-07-31

Phase I

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Budigalimab

  • Condition/Disease

    Non-Small Cell Lung Cancer、 Head and Neck Squamous Cell Carcinoma

  • Test Drug

    ABBV-514ABBV-181 (Budigalimab)

Participate Sites
5Sites

Recruiting5Sites

2019-09-01 - 2024-12-31

Phase I/II

A Phase 1/2 Dose Escalation and Dose Expansion Study of BA3021 in Patients With Advanced Solid Tumors

  • Condition/Disease

    Advanced Solid Tumors

  • Test Drug

    BA3021

Participate Sites
4Sites

Recruiting4Sites

2021-02-26 - 2025-12-10

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2021-01-15 - 2028-12-31

Phase I/II

A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating The Efficacy And Safety Of Multiple Immunotherapy-Based Treatment Combinations In Patients With Metastatic Non-Small Cell Lung Cancer (Morpheus-Lung)

  • Condition/Disease

    Non-Small-Cell Lung

  • Test Drug

    Tecentriq Avastin Docetaxel Accord Ipatasertib Trajenta Sacituzumab Govitecan

Participate Sites
2Sites

Not yet recruiting1Sites

Recruiting1Sites

2022-02-01 - 2026-03-30

Phase I/II

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

1 9 10 11 12 13 15
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB